Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Seq & Ye Shall Find

Philip Seo, MD, MHS  |  Issue: January 2020  |  January 16, 2020

Pikoso.kz / shutterstock.com

Pikoso.kz / shutterstock.com

I nodded, gravely.

I was recently privileged to attend a symposium on eosinophils. I realize that this sounds odd. And it was odd, mainly because I’m not an eosinophil expert. Still, they were in need of someone who knew something about eosinophilic granulomatosis with polyangiitis, so I managed to sneak in through the back door.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As an aside, I think we are on the cusp of a revolution in how we think about diseases mediated by eosinophils. Although we treat them as distinct diagnoses, a tremendous amount of clinical overlap exists between eosinophilic granulomatosis with polyangiitis and other diseases mediated by eosinophils (e.g., chronic eosinophilic pneumonia, eosinophilic esophagitis and other idiopathic hypereosinophilic syndromes). Interestingly, all of these syndromes seem to respond to therapy directed against interleukin 5, regardless of what you call them. Eventually, mepolizumab, reslizumab, benralizumab and other such drugs may unify these diagnoses, in the same way that rituximab has brought together idiopathic orbital pseudotumor, Mikulicz syndrome and idiopathic pancreatitis under the rubric of the IgG4-related diseases.

We are still at just the early stages, however, of understanding diseases mediated by hypereosinophilia. Because of this, at this symposium, we were given a task: propose what we would need to make a breakthrough. Unlike in most grant brainstorming sessions, we were specifically instructed not to consider the cost.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As you could imagine, our proposal quickly spiraled from unlikely to ludicrous. First, we needed substrate: knowing the environment can stimulate eosinophils, we proposed collecting samples from all continents, from patients at all decades of life. We then had to figure out how to characterize these samples. After some back and forth, one of the PhDs in the group exclaimed, “Drop-seq!”

I nodded, gravely.

I was nodding to disguise the fact that I had no idea what he was talking about.

Recently, I’ve been doing a lot of that sort of grave nodding. Seq in these cases stands for sequencing, and the suffix seems to be making its way into a lot of conversations. I know that techniques like PhIP-seq and Drop-seq have dramatically sped the process of discovery. But what do they mean?

Autoantibody Discovery

Let me know when the antibodies come back. As a consultant, I have spoken these words hundreds of times. Autoantibodies are so central to how we think about rheumatic disease, both in terms of classification and patho­genesis, that I am generally loathe to make a final diagnosis if that information is not yet firmly in hand. But how did we come to identify these autoantibodies in the first place?

Consider, for example, mixed connective tissue disease. Undifferentiated connective tissue disease is the catchall label we give patients we suspect have some autoimmune phenomenon that has not yet been given a proper name. Mixed connective tissue disease was first described by Sharp et al. in 1972, when he identified 25 patients who had features of systemic lupus erythematosus, scleroderma and polymyositis.1 Sharp noted these patients were unified by the presence of antibodies against ribonucleic protein (RNP). He described the process of identifying the presence of these anti-RNP antibodies thus:

To study the specificity of antibodies … enzymatic digestion studies were performed. Treatment of the ENA antigen on the red cells with RNase completely eliminated or markedly reduced the agglutination reaction with the patient’s serum in every case of mixed connective tissue disease whereas treatment with trypsin reduced the titer to some extent. Treatment with DNase had no effect. … [T]he speckled pattern of the anti­nuclear fluorescence was eliminated by treatment of tissue sections with RNase but not DNase prior to incubating them with serum from patients with mixed connective tissue disease.

In other words, they conducted a series of experiments to narrow the biochemical properties of the autoantigen. But they also got lucky: The autoantigen just happened to be something that could be affected meaningfully by the reagents they had available.

This observation is not meant, by any means, to denigrate the value of their work. Happen­stance is often a valuable partner in discovery.  There is no particular reason, for example, that antibodies that recognize proteins in the cytoplasm of neutrophils should be associated with glomerulonephritis, but the discovery of anti-neutrophil cytoplasmic antibodies (ANCA) must be one of the most important advances made in our understanding of the systemic vasculitides.2 Similarly, a breakthrough in our understanding of immune-mediated necrotizing myopathies came from the recognition that autoantibodies from some of these patients bound to a protein that was the same molecular weight as 3-hydroxy-3-methyl­glutaryl coenzyme A reductase (HMGCR), an enzyme better known to you as the pharmacologic target of statins.3

The right insight, with the right reagent, at the right time. These are the classic ingredients for autoantibody discovery. And with these ingredients alone we would undoubtedly continue to lurch toward discovery, occasionally achieving new insights, interspersed with long periods of frustrating silence.

Identifying the presence of a specific autoantibody when you have a specific target in mind is not difficult: an autoantibody target (generally, a protein) is bound to the bottom of a plate. Serum from the patient is introduced, and you see if the patient has an antibody that binds to the target. This, in a nutshell, is how the enzyme-linked immunosorbent assay (ELISA) works and is the foundation of the diagnostic antibody testing that keeps Quest Diagnostics and LabCorp in business.

Identifying a novel autoantibody when you don’t know what the target might be is more difficult. If you were using ELISA, you could methodically work your way through every target, one by one. Of course, empires would rise and fall in the time it would take to search through the more than 20,000 proteins manufactured by the human genome.4

Enter PhIP-seq.

One advance in autoantibody discovery came through the use of viruses known as bacteriophages. A phage-display library incorporates human DNA into the viral genome, allowing various human peptides to become part of the viral coat.5 Picture a football stadium in which all the fans were asked to hold banners high over their heads so the cameras could get a good look at each sign. Now, instead of banners, picture every fan holding a small protein fragment; instead of a camera, picture an antibody searching for its target. This is basically how a phage display library works.

The problem with this technique is that not every bit of DNA will be correctly incorporated by the viral genome. Therefore, the proteins expressed by the viruses often represent an incomplete version of reality. Even under the best of circumstances viruses can display only fragments of proteins, not complete proteins with their tertiary structures intact. It’s like reading a sonnet when not every word is successfully printed on the page—you may still see enough to get the gist, or you may just completely miss the point.

Phage immunoprecipitation sequencing (PhIP-seq) uses viruses to display the peptidome: a close-to-complete set of protein fragments encoded by the human genome.6 Because the peptidome uses protein fragments and not complete proteins, not every human autoantibody will be able to find an appropriate target, even with this system. But it allows us to get much closer to this goal than was previously possible.

Of course, this one sentence belies the tremendous complexity of the work that follows: Once an antibody binds a protein, the antecedent DNA must be amplified, then sequenced, to identify the target. But it is not hard to see how this technique could open doors previously slammed shut.

Page: 1 2 3 | Single Page
Share: 

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:Eosinophilianext generation sequencingResearch

Related Articles

    Eosinophilic Gastroenteritis & Eosinophilic Ascites Associated with RA

    June 17, 2019

    Eosinophilic gastroenteritis (EGE) is a rare condition caused by eosinophilic infiltration of the gastrointestinal (GI) tract. The condition is subdivided into the GI layers it affects: mucosal, muscular and subserosal.1 EGE usually presents with non-specific GI symptoms, such as impaired motility, intestinal obstruction and, rarely, ascites.2 Below, we report a rare case of EGE leading…

    Kamolrat/SHUTTERSTOCK.COM

    Eosinophilia: A Diagnostic Evaluation Guide for Rheumatologists

    June 15, 2015

    Clinical Vignette A 45-year-old woman with long-standing asthma and chronic sinusitis has new-onset peripheral neuropathy, arthralgias, fatigue, progressive dyspnea and a nonproductive cough. She has never smoked and has no environmental exposures. Her medications include an albuterol metered-dose inhaler (which she uses daily); an inhaled corticosteroid, montelukast; and ibuprofen (which she takes occasionally). She is…

    This chest CT shows new left upper lobe groundglass opacity.

    Case Report: Could Myocarditis + Shortness of Breath = EGPA?

    August 16, 2019

    Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome or allergic granulomatosis and angiitis, is a rare small- and medium-vessel vasculitis. This disease was first described by American pathologists Jacob Churg and Lotte Strauss in 1951.1 Although the vasculitis is often not apparent in the initial phases of the disease, EGPA can affect any…

    ACR Convergence graphic

    Single-Cell Technologies: A Path for New Insights

    December 7, 2020

    This ACR Convergence session discussed how recent advances in single-cell technologies are being used in rheumatic disease research.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences